Literature DB >> 10808061

GAD autoantibodies in a selection-free population of insulin-treated diabetic patients: indicator of a high prevalence of LADA?

R Schiel1, U A Müller.   

Abstract

UNLABELLED: Up to the present only few data have been available concerning the prevalence of diabetes-specific autoantibodies (anti-GAD, ICA, IAA, IA-2) in unselected populations, in particular in type 2 diabetic patients. Hence, the aim of the present study was to determine the prevalence of anti-GAD in a selection-free population of insulin-treated diabetic patients. Accordingly, 90% of all the insulin-treated diabetic patients (type 1, n=127, type 2, n=117) aged 16-60 years and living in the city of Jena (100242 inhabitants) were examined. In order to test sera for anti-GAD, serum samples were taken in 75% of type 1 (n=95) and in 80% of insulin-treated type 2 diabetic (n=94) patients.
RESULTS: In the group of type 1 diabetic patients 55% of the patients tested were positive for anti-GAD. But, interestingly, in the type 2 group, a total of 21% patients were positive. With respect to this high percentage of anti-GAD positive type 2 diabetic patients it must be suggested that the frequency of patients with latent autoimmune diabetes mellitus in adults (LADA) was underestimated in the past.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10808061     DOI: 10.1016/s0168-8227(00)00139-x

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  2 in total

1.  Prevalence and factors associated with latent autoimmune diabetes in adults (LADA): a cross-sectional study.

Authors:  Anselmo M Manisha; Aminiel R Shangali; Sayoki G Mfinanga; Erasto V Mbugi
Journal:  BMC Endocr Disord       Date:  2022-07-08       Impact factor: 3.263

2.  Lean diabetes in middle-aged adults: A joint analysis of the German DIVE and DPV registries.

Authors:  Bettina Hartmann; Stefanie Lanzinger; Peter Bramlage; Felix Groß; Thomas Danne; Siegfried Wagner; Dietmar Krakow; Artur Zimmermann; Christian Malcharzik; Reinhard W Holl
Journal:  PLoS One       Date:  2017-08-21       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.